Queensland Life Sciences Industry Report 2012 (PDF, 3.5MB)

Queensland Life Sciences Industry Report 2012
64
10.COMMERCIAL INDICATORS
“Existing shareholders contributed the majority of total funds raised
by companies in 2011 (68.8%). While ‘Other private equity’ was also
a significant source of finance (19.9%), Venture capital accounted for
only 2.9% of the total raised in 2011.”
10.1 Commercialisation
10.1.1 Commercialisation — All Respondents
Respondents ranked the strategies they would
likely employ to commercialise their main
technology, product or service. The top three
strategies in 2009 and 2011 are shown in Table 55.
Figure 29 shows the spread of responses for each of
the options. The most likely strategy was in-house
development (Table 55; Figure 29). The strategies
most often referred to as ‘least likely’ in both 2009
and 2011, were an initial public offering (IPO) or the
spinning out of a company.
TABLE 55: Most likely commercialisation strategy to
be employed (90 respondents)
Rank 2011 2009
1 In-house development In-house development
2 Collaborative venture Out-Licensing
3 Out-Licensing Collaborative venture
10.1.2 Commercialisation –
Companies vs. Research Organisations
The highest ranking commercialisation strategies
for companies (74 respondents) and research
organisations (16 respondents) are shown in
Table 56.
TABLE 56: Most likely commercialisation
strategy employed
Rank Companies Research
Organisations
1 In-house development Out-licensing
2 Collaborative venture Collaborative venture
3 Out-Licensing Spin-out company
The majority of companies (40 of 69 companies;
58%) intended to fully commercialise their
technology/product or complete early stage
commercialisation activities (e.g. later stage clinical
development, pilot plant; 12 of 69 companies; 17%),
before realising their primary commercial outcome.
A minority of companies indicated that they planned
to only complete proof-of-concept activities (9%) or
the R&D phase (3%) before realising their primary
commercial outcome.
In contrast, the majority of research organisations
indicated their intention to realise their primary
commercial outcome following completion of
the R&D phase (9 out of 16; 56%) or proof of
concept (5 out of 16; 31%). None intended to take
their technology/product through to early or full
commercialisation.
Figure 29: Strategies respondents will likely employ to commercialise their main technology (90 respondents)